Bank of America CEO Brian Moynihan revealed the company spends over $250 million annually on GLP-1 weight loss medications for its 211,000 employees, a cost that has risen from zero five years ago. This expense now accounts for about 13% of the bank's total $2 billion healthcare budget. Moynihan considers this a valuable investment due to the potential health benefits, including reduced cardiovascular risks and improved employee well-being. The bank also negotiates drug prices aggressively and pairs medication access with health coaching to maximize benefits.
Bank of America (BAC) preferred shares Series NN and QQ currently yield 6.6%, providing an attractive income option compared to long-term U.S. Treasuries. The bank's solid operating results, including rising net interest income and steady loan growth...
Greg Abel, Warren Buffett's successor at Berkshire Hathaway, reduced the company's investment in Bank of America by $1.7 billion. At the same time, he increased the stake in Delta Air Lines by $1.6 billion. This shift in portfolio allocation highligh...
